Division of Thoracic Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Department of General Thoracic Surgery, Ayabe City Hospital, 20-1 Otsuka, Aono-cho, Ayabe, Kyoto, 623-0011, Japan.
Surg Today. 2023 Jun;53(6):655-662. doi: 10.1007/s00595-022-02606-4. Epub 2022 Oct 31.
We assessed the clinical significance of minimal malignant pleural effusion (MPE) using liquid-based cytology (LBC) and immunocytochemistry and reviewed the postoperative outcomes of patients with non-small-cell lung cancer (NSCLC).
We reviewed 240 patients with cM0 NSCLC who underwent lobectomy. Carcinoembryonic antigen (CEA) immunocytochemistry was performed with LBC to aid in the diagnosis of minimal MPE. We assessed the efficacy of this diagnostic method, relevant clinical factors, and postoperative outcomes.
LBC showed positive results in two patients and suspicious results in 21. Of the 21 patients, immunocytochemistry showed minimal MPE in 10 (47.6%); therefore, a total of 12 patients (5%) showed minimal MPE. Minimal MPE is associated with an older age, increased consolidation tumor ratio, and adenocarcinoma histology. The 12 patients with minimal MPE had a 3-year overall survival rate of 90%. Postoperative recurrence was observed in seven patients (58.3%), four of whom were treated with epidermal growth factor receptor-tyrosine kinase inhibitors or immune checkpoint inhibitors, while three are still undergoing treatment, with a survival of 2.2, 2.5 and 5.5 years.
CEA immunocytochemistry offers high sensitivity for the diagnosis of minimal MPE. Surgical intervention may be considered for select patients with NSCLC showing minimal MPE.
我们使用液基细胞学(LBC)和免疫细胞化学评估了少量恶性胸腔积液(MPE)的临床意义,并回顾了非小细胞肺癌(NSCLC)患者的术后结果。
我们回顾了 240 例接受肺叶切除术的 cM0 NSCLC 患者。使用 LBC 进行癌胚抗原(CEA)免疫细胞化学以辅助诊断少量 MPE。我们评估了这种诊断方法的效果、相关临床因素和术后结果。
LBC 在两名患者中呈阳性结果,在 21 名患者中呈可疑结果。在这 21 名患者中,免疫细胞化学显示 10 名(47.6%)存在少量 MPE;因此,共有 12 名患者(5%)存在少量 MPE。少量 MPE 与年龄较大、实变肿瘤比例增加和腺癌组织学有关。12 名少量 MPE 患者的 3 年总生存率为 90%。7 名患者(58.3%)术后复发,其中 4 名接受表皮生长因子受体酪氨酸激酶抑制剂或免疫检查点抑制剂治疗,3 名仍在治疗中,生存时间分别为 2.2 年、2.5 年和 5.5 年。
CEA 免疫细胞化学对少量 MPE 的诊断具有高灵敏度。对于表现出少量 MPE 的 NSCLC 患者,可考虑进行手术干预。